The pepti Journal
Peptide science, decoded.
Honest writing about peptide therapy, the science behind it, and how the access landscape is changing.
19 articles
HHS peptide compounding debate puts BPC-157 and GHK-Cu safety evidence in focus
Federal compounding and clinical-trial records show no change today for Pepti patients using BPC-157 or GHK-Cu while policy questions continue.
Petition asks FDA to set aside July peptide compounding vote
A 22 October 2026 citizen petition asks FDA to disregard a July advisory vote on several compounded peptide substances, with no immediate change for Pepti patients.
Price-guide release puts GLP-1 checkout pricing in focus
A commercial price-guide release says many online GLP-1 sellers advertise below final checkout cost, while primary sources leave prescription and compounding rules unchanged.
WIRED peptide explainer prompts Pepti review of BPC-157, TB-500, PT-141 and kisspeptin facts
A 2 October 2026 consumer video renewed questions about online peptide claims, contamination risk and how patients should interpret FDA and sports-doping records.
Harvard expert warning puts gray-market peptide sourcing back in focus
A 1 October 2026 public-health warning drew a sharp line between gray-market peptide vials and prescription care with quality controls.
KSL peptide segment puts online sourcing risk back in focus
A 1 October 2026 consumer segment cited high mismatch rates in online peptide products, but it does not change prescription requirements or the status of compounded peptide care.
FDA advisers back compounding access for six peptides
An FDA advisory panel voted on 29 September 2026 to recommend 503A compounding access for six peptides, but FDA has not yet made a final decision.
JMCP viewpoint reports negative 18-month ROI for GLP-1 drugs in one managed care analysis
A PubMed-indexed JMCP viewpoint reported negative 18-month return on investment for GLP-1 receptor agonists in one regional managed care population, with adherence and time to benefit central to the authors’ interpretation.
McGill commentary puts BPC-157 and TB-500 sourcing under scrutiny
McGill's science office warned that BPC-157 and TB-500 use is moving faster than the U.S. and Canadian regulatory record, with the clearest patient issue being sourcing rather than a new clinical finding.
Compounded peptides 2026: what patients should know
Compounded peptides 2026 rules are changing fast. Learn what’s legal, what’s risky, and how doctor-prescribed care protects your plan safely.
compounded peptides 2026: legal status of ondansetron & more
compounded peptides 2026: legal status of ondansetron & related meds. Know the new rules, doctor requirements, and your safe options for care.
melanotan II compounded peptide regulations in 2026: what to know
melanotan II compounded peptide regulations in 2026: Get the latest legal status, safety requirements, and what patients should know before starting.
Melanotan II & Compounded Peptides: The Evolving Legal Landscape in 2026
Compounded peptides like Melanotan II face evolving regulations in 2026. What patients need to know about access, safety, and medical oversight.
Compounded Peptides and the Regulatory Reality in 2026
Regulation around compounded peptides like CJC-1295/Ipamorelin/Sermorelin is evolving fast. Here’s what patients and practitioners need to know for 2026.
Compounded Peptides in 2026: New Rules, Patient Impact & CJC-1295/Ipamorelin Access
Curious about compounded peptides like CJC-1295/Ipamorelin in 2026? Here’s what the new regulatory landscape means for patients and prescribers.
Compounded Peptides in 2026: Regulatory Realities & PT-141
Curious about compounded peptide access in 2026? Here’s what’s changed—and what it means for treatments like PT-141.
Navigating Compounded Peptides: Regulatory Insights for 2026
What does the future hold for compounded peptides in 2026? Understanding the regulatory landscape is key for patients considering treatments like Trimix.
Navigating the 2026 Regulatory Landscape for Compounded Peptides
As we approach 2026, understanding the regulatory framework for compounded peptides like Thymosin Beta-4 is crucial for patients and providers.
The Future of Compounded Peptides: Regulatory Landscape in 2026
Explore the evolving regulatory landscape for compounded peptides and what it means for your health in 2026.